5月20日 - ** 医疗设备制造商瑞思迈RMD.N股价下跌3.8%，至244.56美元
** RMD的竞争对手Apnimed周一晚些时候表示，其口服药物在一项治疗阻塞性睡眠呼吸暂停的后期研究中达到了主要目标
** Apnimed公司的试验性药物AD109在衡量轻度、中度和重度阻塞性睡眠呼吸暂停的量表中平均降低了55.1%。
** Apnimed公司称，该药物明显改善了患者的氧合状况，降低了疾病的严重程度
** 该公司计划在 2026 年初向美国 FDA 提交 AD109 药物的上市申请
** 瑞思迈公司生产的持续气道正压机(CPAP)，为睡眠呼吸暂停提供了一种非侵入性治疗选择，睡眠呼吸暂停的特点是睡眠时呼吸短暂中断。
** 包括本届会议的变动在内，RMD 今年累计上涨 10.8
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.